Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors (Q33202550)

23 July 2017

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors (English)

1 reference

23 July 2017

1 reference

ChEBI release 2020-05-28

M J A de Jonge

1

1 reference

23 July 2017

J P Droz

2

1 reference

23 July 2017

L Paz-Ares

3

1 reference

23 July 2017

A T van Oosterom

4

1 reference

23 July 2017

R de Wit

5

1 reference

23 July 2017

P Chollet

6

1 reference

23 July 2017

B Baron

7

1 reference

23 July 2017

D Lacombe

8

1 reference

23 July 2017

K Mettinger

9

1 reference

23 July 2017

P Fumoleau

10

1 reference

23 July 2017

EORTC-New Drug Development Group/New Drug Development Program

11

1 reference

23 July 2017

1 August 2004

1 reference

Investigational New Drugs

23 July 2017

1 reference

23 July 2017

22

1 reference

23 July 2017

329-333

1 reference

23 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02

23 July 2017

0 references

cites work

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

12 December 2020

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

12 December 2020

Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.

1 reference

12 December 2020

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

1 reference

12 December 2020

Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts

1 reference

12 December 2020

A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor

1 reference

12 December 2020

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

12 December 2020

Global cancer statistics

1 reference

12 December 2020

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

1 reference

12 December 2020

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

1 reference

12 December 2020

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

12 December 2020

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue

1 reference

12 December 2020

Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins

1 reference

12 December 2020

10.1023/B:DRUG.0000026260.24275.02

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

0 references

1 reference